Rockwell Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2015. The company develops renal drug therapies and manufactures hemodialysis concentrates and related products. Triferic received FDA approval in January 2015; sales began late in the third quarter. Unless otherwise noted, comparisons are with the corresponding 2014 period.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Sales | $14.38 million | $13.74 million | $41.22 million | $39.74 million |
| Gross profit / margin | $2.50 million / 17.4% | $2.27 million / 16.5% | $6.88 million / 16.7% | $5.97 million / 15.0% |
| Operating loss | $2.57 million | $3.13 million | $9.04 million | $12.54 million |
| Net loss | $2.41 million | $3.97 million | $8.65 million | $14.94 million |
| Loss per share, basic and diluted | $0.05 | $0.10 | $0.17 | $0.37 |
- Revenue and margins: Sales rose 4.6% in Q3 and 3.7% year to date. Gross margin improved in both periods, helped by recognition of Baxter-related deferred license revenue: $0.5 million in Q3 and $1.5 million year to date.
- Expenses: Q3 selling, general and administrative expense declined to $3.83 million from $4.10 million, while year-to-date expense increased to $12.99 million from $12.40 million, mainly reflecting Triferic launch spending. Research and product development costs fell to $2.93 million year to date from $6.10 million after Triferic’s approval.
- Cash flow: Cash used in operations was $13.54 million for the first nine months, versus $13.30 million in 2014. Cash and cash equivalents declined by $32.63 million to $33.17 million; investing activity used $20.66 million, mainly reflecting purchases of available-for-sale investments.
- Liquidity and debt: Cash and investments totaled $73.0 million at September 30, down from $85.7 million at year-end 2014. Current assets were $87.9 million, current liabilities $8.5 million, and working capital $79.4 million. The company reported no debt outstanding.
- Other balance-sheet items: Inventory increased to $7.42 million from $3.92 million, in part to support drug launches. Deferred license revenue was $18.01 million. Available-for-sale investments were $39.82 million; the company reported $0.38 million of year-to-date unrealized losses in other comprehensive income.
Changes, outlook, and risks
- The 2014 fourth-quarter financing and Baxter agreement strengthened liquidity and enabled repayment of the company’s high-interest debt. Under the 10-year Baxter distribution agreement, Baxter distributes concentrate and ancillary products in specified markets and is subject to increasing minimum annual purchase levels. The company retains certain foreign-market rights.
- Management expects the Baxter arrangement to improve operating profit, estimating approximately $1.2 million of annual gross-profit improvement versus the prior domestic concentrate business; this includes deferred license revenue recognition.
- Management stated it expects profitability and positive operating cash flow in the year ahead as drug products gain market penetration. This is an expectation, not quantified formal guidance. Near-term cash needs are expected to include working capital, particularly inventory and receivables. The company also reported discussions with potential partners to out-license products outside the United States.
- Key risks include successful Triferic commercialization and adoption, regulatory and clinical requirements, reliance on third-party drug suppliers, competition and raw-material costs in concentrates, and dependence on Baxter and a limited number of concentrate customers. The filing also identifies possible repayment of a portion of Baxter fees under specified circumstances. Management reported disclosure controls effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Whether Triferic sales and market adoption can support management’s profitability and cash-flow expectations, and the scale of ongoing launch costs and working-capital needs.
- Progress against Baxter’s minimum purchase requirements, the terms and circumstances for any fee repayment, and the realized economics of the distribution agreement.
- Cash burn and the value and liquidity of the short-duration bond-fund investments, including possible effects of interest-rate changes.
- The cover page reports 51,077,877 shares outstanding at October 31, 2015, while the September 30 balance sheet reports 50,227,877 issued and outstanding; verify the subsequent share-count change. The income-statement heading also appears to mislabel the 2014 comparison date; the statements and discussion identify the comparison as September 30, 2014.